Other mutations such as TP53, SMAD4, and CDKN2A have been described in pancreatic adenocarcinoma and carcinoma derived from IPMN, however, their dosage in cystic fluid and their use in clinical practice have not been widely evaluated yet [79]. This evidence concerns the gene SMAD4 and pancreatic intraductal papillary-mucinous neoplasm.